Details for Patent: 11,884,634
✉ Email this page to a colleague
Which drugs does patent 11,884,634 protect, and when does it expire?
Patent 11,884,634 protects OGSIVEO and is included in one NDA.
This patent has eighty patent family members in twenty-nine countries.
Summary for Patent: 11,884,634
| Title: | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| Abstract: | The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1. |
| Inventor(s): | Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee |
| Assignee: | Pfizer Inc |
| Application Number: | US18/057,633 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 11,884,634
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | DISCN | Yes | No | 11,884,634 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-002 | Apr 4, 2024 | RX | Yes | No | 11,884,634 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | RX | Yes | Yes | 11,884,634 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,884,634
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 4010322 | ⤷ Start Trial | CA 2026 00017 | Denmark | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | 301374 | Netherlands | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | C20260011 | Finland | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | LUC50046 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | PA2026516 | Lithuania | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | 122026000026 | Germany | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | 2026C/718 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
